CD93: Recent advances and implications in disease

Current Drug Targets

Volumn 13, Issue 3, 2012, Pages 411-420

  Greenlee Wacker, Mallary C ^a   Galvan, Manuel D ^a,b   Bohlson, Suzanne S ^a,b  

^a UNIVERSITY OF NOTRE DAME   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AA4.1; Adhesion; CD93; Group XIV; Inflammation; Innate immunity

Indexed keywords

CD93 PROTEIN; GELATINASE A; LECTIN; MATRILYSIN; STROMELYSIN; UNCLASSIFIED DRUG;

B LYMPHOCYTE; BONE MARROW CELL; BRAIN ISCHEMIA; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; HEART DISEASE; HEMATOPOIETIC STEM CELL; HUMAN; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTE; MICROARRAY ANALYSIS; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; PERITONITIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPERFUSION; REVIEW; RHEUMATOID ARTHRITIS; STEM CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; THROMBOCYTE; UMBILICAL CORD BLOOD;

ANIMALS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; INFLAMMATION; MEMBRANE GLYCOPROTEINS; MICE; RECEPTORS, COMPLEMENT;

EID: 84857126778     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012799424651     Document Type: Review

References (68)

1. Maia M, Devriese A, Janssens T, et al. CD248 facilitates tumor growth via its cytoplasmic domain. BMC Cancer 2011; 11: 162.
2. Nanda A, Karim B, Peng Z, et al. Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors. Proc Natl Acad Sci USA 2006; 103: 3351-3356.
3. Nepomuceno RR, Henschen-Edman AH, Burgess WH, Tenner AJ. CDNA cloning and primary structure analysis of C1qR(P), the human C1q/MBL/SPA receptor that mediates enhanced phagocytosis in vitro. Immunity 1997; 6: 119-129.
4. Norsworthy PJ, Fossati-Jimack L, Cortes-Hernandez J, et al. Murine CD93 (C1qRp) contributes to the removal of apoptotic cells in vivo but is not required for C1q-mediated enhancement of phagocytosis. J Immunol 2004; 172: 3406-3414.
5. Greenlee MC, Sullivan SA, Bohlson SS. CD93 and related family members: their role in innate immunity. Curr Drug Targets 2008; 9: 130-138.
6. Petrenko O, Beavis A, Klaine M, et al. The molecular characterization of the fetal stem cell marker AA4. Immunity 1999; 10: 691-700.
7. Fonseca MI, Carpenter PM, Park M, et al. C1qR(P), a myeloid cell receptor in blood, is predominantly expressed on endothelial cells in human tissue. J Leukoc Biol 2001; 70: 793-800.
8. McGreal EP, Ikewaki N, Akatsu H, Morgan BP, Gasque P. Human C1qRp is identical with CD93 and the mNI-11 antigen but does not bind C1q. J Immunol 2002; 168: 5222-5232.
9. Dean YD, McGreal EP, Akatsu H, Gasque P. Molecular and cellular properties of the rat AA4 antigen, a C-type lectin-like receptor with structural homology to thrombomodulin. J Biol Chem 2000; 275: 34382-34392.
10. Dean YD, McGreal EP, Gasque P. Endothelial cells, megakaryoblasts, platelets and alveolar epithelial cells express abundant levels of the mouse AA4 antigen, a C-type lectin-like receptor involved in homing activities and innate immune host defense. Eur J Immunol 2001; 31: 1370-1381.
11. Guan E, Robinson SL, Goodman EB, Tenner AJ. Cell-surface protein identified on phagocytic cells modulates the C1q-mediated enhancement of phagocytosis. J Immunol 1994; 152: 4005-4016.
12. Nepomuceno RR, Tenner AJ. C1qRP, the C1q receptor that enhances phagocytosis, is detected specifically in human cells of myeloid lineage, endothelial cells, and platelets. J Immunol 1998; 160: 1929-1935.
13. Bohlson SS, Silva R, Fonseca MI, Tenner AJ. CD93 is rapidly shed from the surface of human myeloid cells and the soluble form is detected in human plasma. J Immunol 2005; 175: 1239-1247.
14. Steinberger P, Szekeres A, Wille S, et al. Identification of human CD93 as the phagocytic C1q receptor (C1qRp) by expression cloning. J Leukoc Biol 2002; 71: 133-1340.
15. Greenlee-Wacker MC, Briseño C., Galvan M, Moriel G, Velázquez P, Bohlson SS. Membrane-associated CD93 regulates leukocyte migration and C1q-hemolytic activity during murine peritonitis. J Immunol. 2011; 187: 3353-3361.
16. Webster SD, Park M, Fonseca MI, Tenner AJ. Structural and functional evidence for microglial expression of C1qR(P), the C1q receptor that enhances phagocytosis. J Leukoc Biol 2000; 67: 109-116.
17. Harhausen D, Prinz V, Ziegler G, et al. CD93/AA4.1: a novel regulator of inflammation in murine focal cerebral ischemia. J Immunol 2010; 184: 6407-6417.
18. Huang H, Auerbach R. Identification and characterization of hematopoietic stem cells from the yolk sac of the early mouse embryo. Proc Natl Acad Sci USA 1993; 90: 10110-10114.
19. Godin I, eterlen-Lievre F, Cumano A. Emergence of multipotent hemopoietic cells in the yolk sac and paraaortic splanchnopleura in mouse embryos, beginning at 8.5 days postcoitus. Proc Natl Acad Sci USA 1995; 92: 773-777.
20. Marcos MA, Morales-Alcelay S, Godin IE, et al. Antigenic phenotype and gene expression pattern of lymphohemopoietic progenitors during early mouse ontogeny. J Immunol 1997; 158: 2627-2637.
21. Yoder MC, Hiatt K, Dutt P, et al. Characterization of definitive lymphohematopoietic stem cells in the day 9 murine yolk sac. Immunity 1997; 7: 335-344.
22. Yamane T, Hosen N, Yamazaki H, Weissman IL. Expression of AA4.1 marks lymphohematopoietic progenitors in early mouse development. Proc Natl Acad Sci USA 2009; 106: 8953-8958.
23. Jordan CT, McKearn JP, Lemischka IR. Cellular and developmental properties of fetal hematopoietic stem cells. Cell 1990; 61: 953-963.
24. Jordan CT, Astle CM, Zawadzki J, et al. Long-term repopulating abilities of enriched fetal liver stem cells measured by competitive repopulation. Exp Hematol 1995; 23: 1011-1015.
25. Trevisan M, Iscove NN. Phenotypic analysis of murine long-term hemopoietic reconstituting cells quantitated competitively in vivo and comparison with more advanced colony-forming progeny. J Exp Med 1995; 181: 93-103.
26. Orlic D, Fischer R, Nishikawa S, Nienhuis AW, Bodine DM. Purification and characterization of heterogeneous pluripotent hematopoietic stem cell populations expressing high levels of c-kit receptor. Blood 1993; 82: 762-770.
27. Danet GH, Luongo JL, Butler G, et al. C1qRp defines a new human stem cell population with hematopoietic and hepatic potential. Proc Natl Acad Sci USA 2002; 99: 10441-10445.
28. Maruyama H, Galvan M, Waffarn F, Tenner AJ. Human cord blood leukocyte innate immune responses to defense collagens. Pediatr Res 2003; 54: 724-731.
29. Ikewaki N, Yamao H, Kulski JK, Inoko H. Flow cytometric identification of CD93 expression on naive T lymphocytes (CD4(+)CD45RA (+) cells) in human neonatal umbilical cord blood. J Clin Immunol 2010; 30: 723-733.
30. Lovik G, Vaage JT, Dissen E, et al. Characterization and molecular cloning of rat C1qRp, a receptor on NK cells. Eur J Immunol 2000; 30: 3355-3362.
31. Zekavat G, Mozaffari R, Arias VJ, et al. A novel CD93 polymorphism in non-obese diabetic (NOD) and NZB/W F1 mice is linked to a CD4+ iNKT cell deficient state. Immunogenetics 2010; 62: 397-407.
32. McKearn JP, Baum C, Davie JM. Cell surface antigens expressed by subsets of pre-B cells and B cells. J Immunol 1984; 132: 332-339.
33. Allman D, Lindsley RC, DeMuth W, et al. Resolution of three nonproliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation. J Immunol 2001; 167: 6834-6840.
34. Chevrier S, Genton C, Kallies A, et al. CD93 is required for maintenance of antibody secretion and persistence of plasma cells in the bone marrow niche. Proc Natl Acad Sci USA 2009; 106: 3895-3900.
35. Greenlee MC, Sullivan SA, Bohlson SS. Detection and characterization of soluble CD93 released during inflammation. Inflamm Res 2009; 58: 909-919.
36. Jeon JW, Jung JG, Shin EC, et al. Soluble CD93 Induces Differentiation of Monocytes and Enhances TLR Responses. J Immunol 2010; 185: 4921-4927.
37. Jutila MA, Rott L, Berg EL, Butcher EC. Function and regulation of the neutrophil MEL-14 antigen in vivo: comparison with LFA-1 and MAC-1. J Immunol 1989; 143: 3318-3324.
38. Kishimoto TK, Jutila MA, Berg EL, Butcher EC. Neutrophil Mac-1 and MEL-14 adhesion proteins inversely regulated by chemotactic factors. Science 1989; 245: 1238-1241.
39. Champagne B, Tremblay P, Cantin A, St PY. Proteolytic cleavage of ICAM-1 by human neutrophil elastase. J Immunol 1998; 161: 6398-6405.
40. Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci 2004; 95: 930-935.
41. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385: 729-733.
42. Boehme MW, Deng Y, Raeth U, et al. Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: in vivo and in vitro studies. Immunology 1996; 87: 134-140.
43. Hundhausen C, Misztela D, Berkhout TA, et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 2003; 102: 1186-1195.
44. Gough PJ, Garton KJ, Wille PT, et al. A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16. J Immunol 2004; 172: 3678-3685.
45. Galkina E, Tanousis K, Preece G, et al. L-selectin shedding does not regulate constitutive T cell trafficking but controls the migration pathways of antigen-activated T lymphocytes. J Exp Med 2003; 198: 1323-1335.
46. Garton KJ, Gough PJ, Raines EW. Emerging roles for ectodomain shedding in the regulation of inflammatory responses. J Leukoc Biol 2006; 79: 1105-1116.
47. Turk BE, Huang LL, Piro ET, Cantley LC. Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nat Biotechnol 2001; 19: 661-667.
48. Tupin E, Kinjo Y, Kronenberg M. The unique role of natural killer T cells in the response to microorganisms. Nat Rev Microbiol 2007; 5: 405-417.
49. Biber K, Sauter A, Brouwer N, Copray SC, Boddeke HW. Ischemia-induced neuronal expression of the microglia attracting chemokine Secondary Lymphoid-tissue Chemokine (SLC). Glia 2001; 34: 121-133.
50. de Haas AH, van Weering HR, de Jong EK, Boddeke HW, Biber KP. Neuronal chemokines: versatile messengers in central nervous system cell interaction. Mol Neurobiol 2007; 36: 137-151.
51. de Jong EK, Dijkstra IM, Hensens M, et al. Vesicle-mediated transport and release of CCL21 in endangered neurons: a possible explanation for microglia activation remote from a primary lesion. J Neurosci 2005; 25: 7548-7557.
52. Kivisakk P, Mahad DJ, Callahan MK, et al. Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc Natl Acad Sci USA 2003; 100: 8389-8394.
53. Baines KJ, Wood LG, Gibson PG. The nutrigenomics of asthma: molecular mechanisms of airway neutrophilia following dietary antioxidant withdrawal. OMICS 2009; 13: 355-365.
54. Wang JS, Liu HC. Systemic hypoxia enhances bactericidal activities of human polymorphonuclear leuocytes. Clin Sci (Lond) 2009; 116: 805-817.
55. Cvetanovic M, Ucker DS. Innate immune discrimination of apoptotic cells: repression of proinflammatory macrophage transcription is coupled directly to specific recognition. J Immunol 2004; 172: 880-889.
56. Voll RE, Herrmann M, Roth EA, et al. Immunosuppressive effects of apoptotic cells. Nature 1997; 390: 350-351.
57. Fadok VA, Bratton DL, Konowal A, et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998; 101: 890-898.
58. Huynh ML, Fadok VA, Henson PM. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest 2002; 109: 41-50.
59. Teder P, Vandivier RW, Jiang D, et al. Resolution of lung inflammation by CD44. Science 2002; 296: 155-158.
60. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. HMGB1: endogenous danger signaling. Mol Med 2008; 14: 476-484.
61. Moosig F, Fahndrich E, Knorr-Spahr A, et al. C1qRP (CD93) expression on peripheral blood monocytes in patients with systemic lupus erythematosus. Rheumatol Int 2006; 26: 1109-1112. Arthritis Foundation- Arthritis types. Available at: www.arthrits.org/ [accessed July 4, 2011].
62. Krafte-Jacobs B, Brilli R. Increased circulating thrombomodulin in children with septic shock. Crit Care Med 1998; 26: 933-938.
63. Conway EM, Nowakowski B. Biologically active thrombomodulin is synthesized by adherent synovial fluid cells and is elevated in synovial fluid of patients with rheumatoid arthritis. Blood 1993; 81: 726-733.
64. van der Net JB, Oosterveer DM, Versmissen J, et al. Replication study of 10 genetic polymorphisms associated with coronary heart disease in a specific high-risk population with familial hypercholesterolemia. Eur Heart J 2008; 29: 2195-2201.
65. Kane JP, Aouizerat BE, Luke M, et al. Novel genetic markers for structural coronary artery disease, myocardial infarction, and familial combined hyperlipidemia: candidate and genome scans of functional SNPs. Int Congress Series 2003; 1262: 309-312.
66. Malarstig A, Silveira A, Wagsater D, et al. Plasma CD93 Concentration is a Potential Novel Biomarker for Coronary Artery Disease. J Intern Med 2011. doi: 10.1111/j.1365-2796.2011.02364.x.
67. Daino K, Ugolin N, tmeyer-Morel S, Guilly MN, Chevillard S. Gene expression profiling of alpha-radiation-induced rat osteosarcomas: identification of dysregulated genes involved in radiation-induced tumorigenesis of bone. Int J Cancer 2009; 125: 612-620.
68. Lee JY, Park AK, Lee KM, et al. Candidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean women. Carcinogenesis 2009; 30: 1528-1531.